14 results about "Coagulation system" patented technology

The invention provides an intelligent dosing control method, device and equipment of a magnetic coagulation system and a storage medium, real-time process data of a plurality of sections of a magnetic coagulation process is collected, standardized time sequence data is generated by performing data cleaning and standardization processing on the real-time process data, feature screening and auxiliary feature construction are performed, and the real-time process data are subjected to data cleaning and standardization processing to generate standardized time sequence data; the expression ability of the key time sequence features is enhanced; a model input feature set is input into a dosing prediction model based on a multi-scale attention mechanism and a bidirectional sequential network, the attention mechanism is utilized to dynamically adjust weight contributions of different features at different moments to a dosing decision, and the bidirectional sequential network is utilized to capture a historical trend and a future dependency relationship at the same time. Quick response and accurate prediction of water quality mutation are realized; the working condition grade is judged based on the effluent quality index, the control instruction is generated in combination with the predicted value, closed-loop control of graded response is formed, it is ensured that the dosing strategy can be adjusted in time under different working conditions, and therefore the technical problem is effectively solved.

This application discloses a nanovesicle, its preparation method, and its application. The nanovesicle includes a core layer containing hemostatic active ingredients; first, second, third, and fourth intermediate layers (collectively forming a shell); and an outer layer (corona). The first intermediate layer is composed of a pH-sensitive polymer material, sensitive to the absolute value of transmembrane pH difference; the second intermediate layer is composed of a hypoxia-sensitive lipid complex; the third intermediate layer is composed of an osmotic pressure-sensitive phospholipid bilayer, sensitive to the absolute value of transmembrane osmotic pressure difference; the fourth intermediate layer is composed of an inflammatory factor / reactive oxygen species-sensitive hydrogel; and the outer layer is composed of a bifunctional polymer brush possessing both temperature difference response and mechanical difference sensing capabilities. This nanovesicle can respond to multidimensional microenvironmental differences between the intravascular and extravascular sides at the bleeding point, orderly disintegrating and releasing hemostatic active ingredients, providing a feasible technical approach for developing precise hemostasis strategies that do not rely on activation of the systemic coagulation system.

A system is described for the regional decoagulation of the blood in an extracorporeal circulation circuit comprising means for infusion of a solution of a citrate or citric acid on the main circuit, which are set upstream of the first filtration unit; means for infusion of a solution for electrolyte restoration on the main circuit, which are set downstream of the filtration unit and a secondary circuit for recirculation of the plasma water obtained by the filtration unit. The secondary circuit comprises: a first cartridge comprising an anion-exchange resin charged with chlorine ions; a second cartridge comprising a cation-exchange resin charged with sodium and potassium ions, which is set downstream of the first cartridge and means for removal of a first fraction of the plasma water obtained by the filtration unit.

This invention belongs to the field of biomedicine and relates to a procoagulant polypeptide TPTX and its applications. The procoagulant polypeptide TPTX of this invention can exert its procoagulant and hemostatic effects by specifically inhibiting plasmin activity. Experiments have shown that TPTX exhibits significant dose-dependent procoagulant and hemostatic effects in ferric chloride-induced mouse carotid artery thrombosis models, mouse liver hemorrhage models, mouse tail hemorrhage models, and mouse saphenous vein hemorrhage models, with effects superior to the positive control drug 6-aminocaproic acid. Simultaneously, TPTX can reduce the area of ​​atorvastatin-induced cerebral hemorrhage in zebrafish and improve their motor dysfunction. Mechanistic studies show that TPTX has an inhibitory constant Ki of 17.76 nM on plasmin and has no significant effect on the activity of seven other key serine proteases in the coagulation system, demonstrating a clear target and high selectivity. The procoagulant polypeptide of this invention can be used to prepare hemostatic drugs, possessing the advantages of high efficiency, clear target, and high selectivity, with broad prospects for clinical application.

The application discloses an oil-in-water probiotic emulsion based on a heterologous protein complex coagulation system and a preparation method and application thereof. The preparation method is as follows: first, a mixed solution of lactoferrin and bone bridge protein is prepared, and then the solution is stirred and dissolved at room temperature to hydrate; the pH is adjusted to 4.6-5.4 to obtain an aqueous phase; probiotic powder is dispersed in medium-chain triglyceride to obtain an oil phase; and the aqueous phase and the oil phase are mixed and homogenized to obtain the oil-in-water probiotic emulsion. The application has the advantages of simple preparation process, low cost, no need to add an emulsifier, no need to heat and add a crosslinking agent for strengthening the stability of the aqueous phase, high embedding rate of the oil-in-water emulsion probiotic, double protection, improved gastrointestinal tolerance and environmental resistance of the probiotic in the emulsion, and prolonged shelf life of the product, which expands the application of the probiotic and the protein in the food field.

The utility model discloses a coagulation system flushing device, which relates to the technical field of flushing and comprises a movable barrel, a built-in barrel is slidably mounted on the inner side of the movable barrel, a support plate is arranged on the surface of the movable barrel, a flushing pump is fixedly mounted on the surface of the support plate, and a positioning ring is fixedly mounted on the surface of the support plate. According to the washing equipment for the coagulation system, an operator can slide out of the inner side of the positioning ring by pulling the positioning supporting column, then the operator controls the support plate to rotate and adjust on the surface of the movable barrel through the rotating supporting rod, and then the built-in barrel is not limited by the support plate any more; the built-in barrel is arranged in the movable barrel, so that the built-in barrel can be taken out from the inner side of the movable barrel for cleaning operation, and the defects of low efficiency, poor treatment effect and serious waste of dichloromethane caused by the fact that the blocked parts of a traditional coagulation system need to be detached individually and soaked with dichloromethane or washed with a gun head are overcome.

This invention discloses a method for surface-modified biomaterials and a modified pericardial material, relating to the field of biomedical materials technology. The method includes the following steps: S1, providing animal pericardial material cross-linked with glutaraldehyde; providing a bridging molecule containing a first bridging group and a second bridging group, and a phosphorylcholine polymer with a third bridging group at its end; binding the first bridging group to an aldehyde group on the surface of the pericardial material via a first covalent reaction; binding the second bridging group to the third bridging group via a second covalent reaction, thereby achieving grafting of the phosphorylcholine polymer onto the material surface; the first covalent reaction and / or the second covalent reaction include Schiff base formation and reductive amination processes. The modified pericardial material prepared in this application introduces a phosphorylcholine biomimetic coating, which can improve blood compatibility on the material surface, reduce activation of the coagulation system and platelet adhesion, and inhibit the initiation of calcium ion deposition on the material surface, while exhibiting high safety.

The invention discloses a method for analyzing MOGAD characteristics by using blood coagulation-related differential proteins, relates to the technical field of analysis of MOGAD characteristics by using differential proteins, and is used for carrying out joint analysis on various related proteins participating in blood coagulation cascade reaction, anticoagulation regulation and fibrinolysis processes in serum of MOGAD patients so as to construct a protein expression mode reflecting MOGAD related blood coagulation abnormal characteristics. By comparing the difference of the overall expression characteristics of blood coagulation related proteins between an MOGAD patient and a healthy control group or a non-MOGAD inflammatory demyelinating disease patient, the abnormal state of a blood coagulation system related to the occurrence and pathological process of the MOGAD disease is identified, so that the systematic characteristic change of the MOGAD on the blood coagulation function level is revealed; according to the method disclosed by the invention, the expression characteristics of the blood coagulation related protein in the serum of the MOGAD patient are systematically screened and quantitatively analyzed, and the functional change of the blood coagulation system is introduced into the MOGAD disease characteristic research, so that the expansion from a single immune index to multi-dimensional biological characteristic analysis is realized.

The invention discloses a method for surface modification of a biological material and a modified pericardium material, and relates to the technical field of biomedical materials. The method comprises the following steps: S1, providing an animal pericardium material subjected to glutaraldehyde crosslinking treatment; providing a bridging molecule comprising a first bridging group and a second bridging group, and a phosphorylcholine polymer terminal-modified with a third bridging group; combining the first bridging group with the aldehyde group on the surface of the pericardium material through a first covalent reaction; combining the second bridging group with the third bridging group through a second covalent reaction to realize grafting of the phosphorylcholine polymer on the surface of the material; the first covalent reaction and / or the second covalent reaction comprise Schiff base formation and reductive amination processes. According to the prepared modified pericardium material, the phosphorylcholine bionic coating is introduced, the surface blood compatibility of the material can be improved, blood coagulation system activation and platelet adhesion can be reduced, deposition starting of calcium ions on the surface of the material can be inhibited, and safety is high.

The present application relates to the field of medical diagnosis, and specifically provides a risk assessment model for venous thromboembolism (VTE) of Chinese population and application thereof. The model is based on the genetic characteristics of Chinese population, and contains 15 genetic variables (SNPs) related to the pathophysiological mechanism of VTE, covering five aspects of anticoagulation system, coagulation system, fibrinolysis system, platelet system and vascular endothelial system. The model assesses the genetic risk of VTE of patients by calculating VTE-PRS-15 value, and determines the comprehensive risk grade of patients in combination with Caprini clinical assessment scale. The present application also provides a corresponding genetic polymorphism detection kit. According to clinical data verification, the model improves the accuracy and practicability of VTE risk assessment.

Provided is a rotary incision coagulation system, which comprises: a rotary incision apparatus, used for performing a rotary incision operation on a tissue; a coagulation electrode, used for performing a coagulation operation on a wound surface; and a control host, comprising a power supply module, a rotary incision control module, and a coagulation control module. The power supply module is used for supplying power to the rotary incision control module and the coagulation control module, the rotary incision control module is connected to the rotary incision apparatus and used for controlling the operation of the rotary incision apparatus, and the coagulation control module is connected to the coagulation electrode and used for controlling the operation of the coagulation electrode. On the basis of the rotary incision function of the traditional rotary incision system, the rotary incision coagulation system adds an electrocoagulation hemostasis function, and has the advantages of simple structure, convenient use, a wide application range, and the like. Compared with the solution in which a rotary incision device and an electrocoagulation device are separately arranged, the space can be saved.

The invention discloses a coagulation system with a built-in calcium fluoride crystallizer. A first-stage coagulation tank is communicated with the bottom of a second-stage coagulation tank, wherein a water outlet is formed in the side wall of the upper end of the second-stage coagulation tank; the calcium fluoride crystallizer comprises an outer guide cylinder fixed in the primary coagulating basin, an inner guide cylinder inserted in the outer guide cylinder, a water inlet pipe inserted in the inner guide cylinder from top to bottom and a chemical inlet pipe inserted between the outer guide cylinder and the inner guide cylinder, the upper edge of the outer guide cylinder is higher than the liquid level of the primary coagulating basin, and the lower end of the inner guide cylinder extends out of the outer guide cylinder; the height of a circle of water passing holes formed in the side wall of the upper end of the inner guide cylinder is lower than the height of the liquid level of the first-stage coagulating basin, wastewater flows along the inner guide cylinder from top to bottom, and the wastewater in the first-stage coagulating basin flows into an annular gap between the inner guide cylinder and the outer guide cylinder from bottom to top; according to the invention, the existing coagulating basin can be transformed with high efficiency and low cost, and the crystallization rate of calcium fluoride is greatly improved.

The invention relates to the field of medical diagnosis, in particular to a risk assessment model suitable for venous thromboembolism (VTE) of Chinese population and application of the risk assessment model. The model is based on genetic characteristics of Chinese population, comprises 15 genetic variables (SNP) related to a VTE pathophysiology mechanism, and covers five aspects of an anticoagulation system, a blood coagulation system, a fibrinolytic system, a platelet system and a vascular endothelial system. According to the model, the VTE genetic risk of a patient is evaluated by calculating a VTE-PRS-15 value, and the comprehensive risk level of the patient is determined by combining with a Caprini clinical evaluation scale. The invention also provides a corresponding gene polymorphism detection kit. Clinical data verifies that the model improves the accuracy and practicability of VTE risk assessment.